Comparison of Enochian Biosciences Inc. (ENOB) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

As Biotechnology companies, Enochian Biosciences Inc. (NASDAQ:ENOB) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are our subject to contrast. And more specifically their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Enochian Biosciences Inc. N/A 0.00 28.14M -0.82 0.00
Regeneron Pharmaceuticals Inc. 6.71B 6.61 2.44B 20.71 20.95

Table 1 shows the gross revenue, earnings per share and valuation for Enochian Biosciences Inc. and Regeneron Pharmaceuticals Inc.


Table 2 shows us the return on equity, return on assets and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Enochian Biosciences Inc. 0.00% -18.7% -16.7%
Regeneron Pharmaceuticals Inc. 36.36% 32.2% 23.4%

Volatility & Risk

A 0.69 beta means Enochian Biosciences Inc.’s volatility is 31.00% less than Standard & Poor’s 500’s volatility. Competitively, Regeneron Pharmaceuticals Inc.’s 20.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 1.2 beta.


8.1 and 8.1 are the respective Current Ratio and a Quick Ratio of Enochian Biosciences Inc. Its rival Regeneron Pharmaceuticals Inc.’s Current and Quick Ratios are 4.5 and 3.9 respectively. Enochian Biosciences Inc. has a better chance of clearing its pay short and long-term debts than Regeneron Pharmaceuticals Inc.

Analyst Ratings

In next table is given Enochian Biosciences Inc. and Regeneron Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Enochian Biosciences Inc. 0 0 0 0.00
Regeneron Pharmaceuticals Inc. 0 5 2 2.29

Regeneron Pharmaceuticals Inc. on the other hand boasts of a $436.33 average price target and a 7.05% potential upside.

Institutional and Insider Ownership

Roughly 0% of Enochian Biosciences Inc. shares are held by institutional investors while 72.7% of Regeneron Pharmaceuticals Inc. are owned by institutional investors. Insiders held roughly 0.1% of Enochian Biosciences Inc.’s shares. Insiders Comparatively, held 0.9% of Regeneron Pharmaceuticals Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Enochian Biosciences Inc. -11.36% 2.31% -5.29% 41.36% 17.35% -5.28%
Regeneron Pharmaceuticals Inc. 3.2% 1.06% 19.3% 6.69% 34.82% 16.15%

For the past year Enochian Biosciences Inc. had bearish trend while Regeneron Pharmaceuticals Inc. had bullish trend.


On 10 of the 11 factors Regeneron Pharmaceuticals Inc. beats Enochian Biosciences Inc.

Enochian Biosciences Inc., a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients. Enochian BioSciences is headquartered in Los Angeles, California.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; and the U.S. Department of Health and Human Services to develop treatments combating infectious diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.